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Abstract 
The chemical functionalization of cell-surface proteins of human primary fetal bone cells with 
hydrophilic bioorthogonal intermediates was investigated. Toward this goal, chemical 
pathways were developed for click reaction-mediated coupling of alkyne derivatives with 
cellular azido-expressing proteins. The incorporation via a tetraethylene glycol linker of a 
dipeptide and a reporter biotin allowed the proof of concept for the introduction of cell-
specific peptide ligands and to follow the reaction in living cells. Tuning the conditions of the 
click reaction resulted in chemical functionalization of living human fetal osteoblasts with 
excellent cell survival.  
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Introduction 
During the last decade, bioorthogonal chemical reactions have been developed to probe 
biomolecules in living systems.1-5 The chemical motifs involved in these reactions include 
peptide sequence with specific side chain combinations, carbonyl moieties for condensation 
with aminooxy or hydrazides probes, and azides for Staudinger ligation with 
triarylphosphines and cycloadditions to alkynes.6,7 The biocompatibility of these reactions 
provides efficient tools for the modification of proteins, the labeling of enzymes, the 
metabolic labeling of cell-surface glycans and lipids within their native cellular environment 
and thus allows to study the biological processes in which these biomolecules are involved. 
Further development of highly reactive bioorthogonal reagents, avoiding the use of metal 
promoters,8-14 extended the application of these probing methodologies to living cells and 
animals.  
A promising approach in tissue engineering is to seed implants with the cells of interest prior 
to implantation. Such an approach may request chemical functionalization of the cell surface. 
Human fetal cells have an interesting potential for therapeutic use in tissue engineering and 
regeneration, including bone tissue engineering, due to their rapid growth rate and their ability 
to differentiate in vitro into mature osteoblasts as well as their histocompatibility,15-17 
eliminating the need for anti-graft rejection medication of the patients.  
For further development of bone implants, we aimed to develop means to chemically 
functionalize human fetal osteoblasts toward future application of these modified cells in 
implant biomaterials. As small peptides18,19 can promote cell adhesion and proliferation, we 
have focused on the development of hydrophilic ligands containing amino acid residues. 
Here, the use of copper-mediated and copper-free catalyzed azide-alkyne [3+2] dipolar 
cycloaddition was investigated for the covalent functionalization of cell-surface proteins of 
human primary fetal osteoblasts. Chemical ligands containing amino acid residues, a terminal 
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alkyne for functionalization of cell surface proteins through copper-mediated and copper-free 
[3+2] dipolar cycloadditions and a biotin label for probing cell functionalization were 
designed and synthesized. Then their potential to covalently functionalize human fetal 
osteoblasts was evaluated. The efficiency of the coupling reaction was determined using the 
reporter biotin conjugate, as previously used in a different cellular model,20,21 and the long-
term survival of the functionalized cells following the click reactions was optimized. 
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Experimental Procedures 
General methods 
Commercial reagents (Fluka, Aldrich, Bachem) were used without purification. Anhydrous 
solvents were obtained by filtration. Liquid/solid flash chromatography (FC): columns of 
silica gel (0.040-0.63 mm, Merck No.9385 silica gel 60, 240-400 mesh). Eluent: mixture of 
light petroleum ether (PE) and ethyl acetate (EtOAc) or mixture of dichloromethane (DCM) 
and methanol (MeOH). TLC for reaction monitoring: Merck silica gel 60 F254 plates; 
detection by UV light; Pancaldi reagent, KMnO4, ninhydrine or phosphomolybdic acid. IR 
spectra: Perkin-Elmer-1420 spectrometer. 1H NMR spectra: Bruker-ARX-400 spectrometer 
(400 MHz); δ(H) in ppm relative to the solvent's residual 1H signal [CHCl3, δ(H) 7.27, 
MeOD, δ(H) 3.31] as internal reference; 13C NMR spectra: same instrument as above (100.6 
MHz); δ(C) in ppm relative to solvent's C-signal [CDCl3, δ(C) 77.1, MeOD, δ(C) 49.0] as 
internal reference. GC-MS spectrometer (Nermag R-10-10C, chemical ionization (NH3) 
mode m/z); MALTI-TOF spectrometer (Axima-CFR+, Kratos, Manchester); ESI-Q 
spectrometer (Finnigan SSQ 710C, Thermoquest, UK); ESI-QT spectrometer (Ultima 
spectrometer, Micromass, Manchester). 
 
Syntheses 
Tert-butyl N2-[9A fluoren-9-ylmethoxy)carbonyl]-N-3,6,9,12-tetraoxa-pentadec-14-yn-1-
yl-L-α-glutaminate (5). Fmoc-glu-(OtBu)-OH (360 mg, 0.9 mmol, 1 equiv) and PyBOP (540 
mg, 1.0 mmol, 1.2 equiv) were dissolved in DCM (8 mL). DIPEAa (0.3 mL, 1.7 mmol, 2 
equiv) was added, followed by a solution of 322 (200 mg, 0.9 mmol, 1 equiv) in 
dichloromethane (4 mL) at 0 °C. After 15 min, the reaction mixture was warmed to 25 °C and 
stirred for 12 h. The solvent was removed under reduced pressure and the resulting mixture 
was dissolved in EtOAc. This solution was washed with saturated NH4Cl, H2O, 5 % NaHCO3 
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and finally with saturated NaCl. The organic phase was dried over anhydrous MgSO4, filtered 
and concentrated under reduced pressure. The product was purified by flash column 
chromatography (EtOAc/petroleum ether 2:1 then 3:1) (332 mg, 60 %). IR (film): 3285, 2870, 
1715, 1665, 1520, 1450, 1390, 1350, 1245, 1150, 1085, 1045, 950, 840, 760, 740, 645, 620, 
555, 540, 515, 500 cm-1. 1H NMR (400 MHz, CDCl3): δ=7.76 (d, 3J= 7.5 Hz, 1H, Harom), 7.60 
(d, 3J= 7.4 Hz, 1H, Harom), 7.40 (t, 3J= 7.4 Hz, 1H, Harom), 7.32 (t, 3J= 7.4 Hz, 1H, Harom), 
6.75 (s, 1H, NH), 5.83 (s, 1H, NH), 4.41 (m, 2H, H-1’’), 4.21 (m, 4H, H2-13, H-9, H-2), 3.69-
3.45 (m, 16H, (CH2-O)8), 2.36 (m, 2H, H-4, H2-3), 2.01 (m, 3H, H-4, H2-3, H-15), 1.46 (s, 
9H, (CH3)3). 13C NMR (100 MHz, CDCl3): δ=172.7, 171.9, 143.8, 141.3, 127.7, 127.1, 125.1, 
119.9, 80.7, 74.7, 70.2, 70.1, 70.0, 69.9, 68.6, 67.0, 58.3, 54.4, 47.2, 39.3, 31.6, 28.1. HRMS 
(ESI): (m/z): calcd for C35H46N2O9+H: 639.3282, found: 639.3292. [α]D25 = - 22 (c=0.085, 
CH2Cl2). 
Tert-butyl N2-[4-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl-pentanoyl]-N-(3,6,9,12-
tetraoxapentadec-14-yne-1-yl)-L-α-glutaminyl-L-phenylalaninate (9). N2-[9A fluoren-9-
ylmethoxy)carbonyl]-N-3,6,9,12-tetraoxa-pentadec-14-yn-1-yl-L-α-glutaminate 5 (536 mg, 
0.84 mmol, 1 equiv) was dissolved into a solution of 4 M HCl in dioxane (3.20 mL) at 25 °C. 
After stirring for 1h the solvent was removed and HCl was coevaporated in presence of 
acetonitrile to afford acid 6 as a white solid (420 mg, 86 %). N2-[9A fluoren-9-
ylmethoxy)carbonyl]-N-3, 6, 9, 12-tetraoxa-pentadec-14-yn-1-yl-L-α-glutaminate 6 (100 mg, 
0.17 mmol, 1 equiv) and PyBOP (107 mg, 0.21 mmol, 1.2 equiv) were dissolved in dry DCM 
(1.6 mL). Triethylamine (88 μL 0.51 mmol, 3 equiv) was added at -5 °C. A solution of L-Phe-
OtBu (44 mg, 0.17 mmol, 1 equiv) in DCM (1.2 mL) was added dropwise. The reaction 
mixture was stirred until total conversion of the starting material (monitored by TLC). The 
solvent was removed under reduced pressure and EtOAc was added. The organic phase was 
washed with saturated NH4Cl, H2O and finally aqueous 5 % NaHCO3. The resulting mixture 
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was dried over anhydrous MgSO4, filtered and concentrated. The product 7 was purified by 
flash column chromatography (CH2Cl2/MeOH: 95:5) to afford a colorless oil (100 mg, yield 
75 %). Tert-butyl N2-[9A fluoren-9-ylmethoxy)carbonyl]-N-(3,6,9,12-tetraoxa-pentadec-14-
yn-1-yl)-L-α-glutaminyl-L-phenylalaninate 7 (100 mg, 0.13 mmol, 1 equiv) was dissolved 
into a solution of 20 % piperidine in DMF (2.5 mL) at 25 °C. After stirring for 1h the solvent 
was evaporated and piperidine was removed by coevaporation with toluene. The product was 
purified by flash column chromatography (CH2Cl2/MeOH: 95:5) to afford a colorless oil (17 
mg, 18 %). Tert-butyl N-(3,6,9,12-tetraoxa-pentadec-14-yn-1-yl)-L-α-glutaminyl-L-
phenylalaninate (17 mg, 0.03 mmol, 1 equiv) and biotin-OSu (10 mg, 0.03 mol, 1 equiv) were 
dissolved in DMF (0.3 mL) at 25 °C. Triethylamine (6.3 μL, 0.05 mmol, 1.5 equiv) was 
added. The reaction mixture was stirred for 12 h at 25 °C. The solvent was removed and the 
product was purified by HPLC (XTerra Prep RP C18, (19x150 mm Waters)) to afford 9 as a 
colorless oil (7 mg, 30 %). IR (film): 3275, 2925, 2860, 2405, 1645, 1535, 1455, 1365, 1255, 
1200, 1150, 1095, 1030, 840, 700, 605, 580, 570, 520 cm-1. 1H NMR (400 MHz, MeOD): 
δ=7.25 (m, 5H, Harom), 4.54 (dd, 2J= 8.2, 3J= 6.7 Hz, H-6a), 4.49 (dd, 1H, 2J= 7.8, 3J= 4.8 
Hz, H-2, H-2’ ), 4.30 (dd, 1H, 2J= 7.8, 3J= 4.4 Hz, H-2, H-2’), 4.25 (dd, 1H, 2J= 8.2, 3J= 6.4 
Hz, H-3a), 4.18 (d, 2H, 4J= 2.4 Hz, H-13), 3.67-3.34 (m, 16H, (CH2-O)8, 3.20 (m, 1H, H-
4’’’), 3.07 (dd, 1H, 2J= 13.8, 3J= 6.7 Hz, H2-3), 2.98 (dd, 1H, 2J= 13.8, 3J= 5.5 Hz, H2-3), 
2.92 (dd, 1H 2J= 12.7, 3J= 5.0 Hz, H2-6’’’), 2.85 (t, 1H, 3J= 2.4 Hz, H-15), 2.70 (d, 1H, 3J= 
12.7 Hz, H2-6’’’), 2.27 (m, 4H, (CH2)2), 199-1.44 (m, 8H, (CH2)4), 1.42 (s, 9H, (CH3)3). 13C 
NMR (100 MHz, MeOD): δ=176.0, 174.8, 173.9, 172.7, 166.2, 138.2, 130.4, 129.4, 127.9, 
83.0, 76.0, 71.5, 71.5, 71.3, 71.2, 70.4,  70.1, 63.2, 61.6, 59.0, 56.9, 55.9, 54.2, 41.0, 40.4, 
38.6, 36.4, 32.8, 29.6, 29.4, 29.0, 28.2, 26.6. HRMS (ESI): (m/z): calcd for C39H59N5O10S+H: 
790.4061, found: 790.4073. [α]D25 = - 55 (c=0.04, CH2Cl2). 
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Tert-butyl N2-[5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-pentanoyl]-N-
(3,6,9,12-tetraoxapentadec-14-yne-1-yl)-L-α-glutaminyl-L-prolinate (10). N2-[9A fluoren-
9-ylmethoxy)carbonyl]-N-3,6,9,12-tetraoxa-pentadec-14-yn-1-yl-L-α-glutaminate 5 (100 mg, 
0.17 mmol, 1 equiv) and PyBOP (107 mg, 0.21 mmol, 1.2 equiv) were dissolved in dry DCM 
(1.6 mL). Triethylamine (88 μL, 0.51 mmol, 3 equiv) was added at -5 °C. A solution of L-
Pro-OtBu (36 mg, 0.17 mmol, 1 equiv) in DCM (1.2 mL) was added dropwise. The reaction 
mixture was stirred until total conversion of the starting material. The solvent was removed 
under reduced pressure and EtOAc was added. The organic phase was washed with saturated 
NH4Cl, H2O and finally 5 % NaHCO3. The resulting mixture was dried over anhydrous 
MgSO4, filtered and concentrated. The product was purified by flash column chromatography 
(CH2Cl2/MeOH: 95:5) to afford a colorless oil (81 mg, yield 65 %). Tert-butyl N2-[9A 
fluoren-9-ylmethoxy)carbonyl]-N-(3,6,9,12-tetraoxa-pentadec-14-yn-1-yl)-L-α-glutaminyl-L-
prolinate 8 (81 mg, 0.11 mmol, 1 equiv) was dissolved into a solution of 20 % piperidine in 
DMF (2.2 mL) at 25 °C. After stirring for 1h the solvent was evaporated and piperidine was 
removed by coevaporation with toluene. The product was purified by flash column 
chromatography (CH2Cl2/MeOH: 95:5 then 9:1) to afford a colorless oil (34 mg, 60 %). Tert-
butyl N-(3,6,9,12-tetraoxa-pentadec-14-yn-1-yl)-L-α-glutaminyl-L-prolinate (34 mg, 0.07 
mmol, 1 equiv) and biotin-OSu (23 mg, 0.07 mol, 1 equiv) were dissolved in DMF (0.7 mL) 
at 25 °C. Triethylamine (13.8 μL, 0.99 mmol, 1.5 equiv) was added. The reaction mixture was 
stirred at 25 °C for 12 h. The solvent was removed and the product was purified by HPLC 
(XTerra Prep RP C18, (19x150 mm Waters)) to afford 10 as a colorless oil (12 mg, 25 %). IR 
(film): 3270, 2870, 2475, 1640, 1535, 1445, 1345, 1245, 1200, 1090, 1035, 940, 840, 650, 
605, 595, 530, 520 cm-1. 1H NMR (400 MHz, MeOD): δ =4.48 (m, 1H, H-6a), 4.33 (m, 2H, 
H-3a, H-2), 4.19 (d, 2H, 4J= 2.3 Hz, H2-13), 3.68-3.54 (m, 16H, (CH2-O)8), 3.42 (m, 2H, H2-
5), 3.21 (m, 1H, H-4), 2.93 (dd, 1H, 2J= 12.7, 3J= 5.0 Hz, H2-6) 2.86 (t, 1H, 3J= 2.4 Hz, H-
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15), 2.71 (d, 1H, 2J= 12.7 Hz, H2-6), 2.48-1.56 (m, 16H, (CH2)8), 1.47, (s, 9H, (CH3)3).13C 
NMR (100 MHz, MeOD): δ =176.1, 173.3, 173.2, 82.7, 76.0, 71.6, 71.6, 71.3, 70.5, 70.1, 
63.3, 61.7, 61.1, 59.1, 57.0, 54.3, 48.4, 41.1, 40.6, 40.4, 36.5, 31.6, 30.3, 29.6, 29.4, 29.3, 
28.3, 26.7, 25.6. HRMS (ESI): (m/z): calcd for C35H57N5O10S+H: 740.3904, found: 740.3927. 
[α]D25 = - 31 (c=0.035, CH2Cl2).  
N-(Tert-butoxycarbonyl)glycyl-N-(2-{2-[2-(2-hydroxyethoxy) 
ethoxy]ethoxy}ethyl)prolinamide (11) Triethylamine (2.3 mL, 16.5 mmol, 3 equiv) and 
PyBOP (3.2 g, 6.1 mmol, 1.1 equiv) were added to a solution of Boc-Gly-Pro (1.5 g, 5.5 
mmol, 1 equiv) in DCM (26 mL). After 15 minutes 2-(2-(2-(2-
aminoethoxy)ethoxy)ethoxy)ethanol (1.1 g, 5.5 mmol, 1 equiv) in DCM (26 mL) was added. 
The reaction mixture was stirred until total conversion of the starting material (monitored by 
TLC). The solvent was removed under reduced pressure and the product was purified by 
column chromatography (CH2Cl2/MeOH 95:5) to afford a colorless oil (2.34 g, 95 %). IR 
(film): 3410, 2875, 2495, 1650, 1440, 1365, 1250, 1165, 1120, 980, 840, 630, 540, 505 cm-1. 
1H NMR (400 MHz, MeOD): δ=4.44 (dd, 2J= 8.6, 3J= 2.8 Hz, 1Ha, H-2) 4.40 (dd, 2J= 8.6, 
3J= 3.7 Hz, 1Hb, H-2), 3.91 (m, H2-2’), 3.68-3.35 (m, 18H, (CH2-O)6, CH2-OH, H2-5), 3.22 
(q, N+H(CH2CH3)3), 2.35-1.86 (m, 4H, H2-3, H2-4), 1.45 (s, 9H, (CH3)3), 1.31 (t, 
N+H(CH2CH3)3).13C NMR (100 MHz, MeOD): δ=174.6, 170.5, 158.5, 80.6, 73.6, 71.6, 71.3, 
71.2, 71.1, 70.4, 70.3, 62.2, 61.9, 61.4, 47.6, 43.8, 40.4, 40.5, 33.3, 30.7, 28.7, 25.6, 23.40. 
HRMS (ESI): (m/z): calcd for C20H37N3O8+H: 448.2659, found: 448.2658. [α]D25 = - 26 
(c=0.09, CH2Cl2). 
Tert-butyl N2-[5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-pentanoyl]-N-
(3,6,9,12-tetraoxa-pentadec-14-yn-1-yl)-L-α-glutaminylglycyl-N-(2-{2-[2-(2-
hydroxyethoxy) ethoxy]ethoxy}ethyl)-L-prolinamide (12) N2-[9A fluoren-9-
ylmethoxy)carbonyl]-N-3,6,9,12-tetraoxa-pentadec-14-yn-1-yl-L-α-glutaminate 6 (100 mg, 
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0.17 mmol, 1 equiv) and PyBOP (107 mg, 0.21 mmol, 1.2 equiv) were dissolved in dry DCM 
(1.6 mL). Triethylamine (88 μL, 0.51 mmol, 3 equiv) was added at -5 °C. A solution of 
glycyl-N-(2-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}ethyl)-L-prolinamide 11 (60 mg, 0.17 
mmol, 1 equiv) in DCM (1.2 mL) was added dropwise. The reaction mixture was stirred until 
total conversion of the starting material (monitored by TLC). The solvent was removed under 
reduced pressure and EtOAc was added. The organic phase was washed with saturated 
NH4Cl, H2O and finally 5 % NaHCO3. The resulting mixture was dried over anhydrous 
MgSO4, filtered and concentrated. The product was purified by flash column chromatography 
(CH2Cl2/MeOH: 9:1) to afford a colorless oil (20 mg, yield 12 %). Tert-butyl N2-[9A fluoren-
9-ylmethoxy)carbonyl]-N-(3,6,9,12-tetraoxa-pentadec-14-yn-1-yl)-L-α-glutaminylglycyl-N-
(2-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}ethyl)-L-prolinamide (20 mg, 0.02 mmol, 1 equiv) 
was dissolved into a solution of 20 % piperidine in DMF (0.5 mL) at 25 °C. After stirring for 
1h the solvent was evaporated and piperidine was removed by coevaporation with toluene. 
The product was purified by flash column chromatography (CH2Cl2/MeOH: 9:1 then 
CH3CN/NH4: 5:1) to afford a colorless oil (13 mg, 86 %). Tert-butyl N-(3, 6, 9, 12-tetraoxa-
pentadec-14-yn-1-yl)-L-α-glutaminylglycyl-N-(2-{2-[2-(2-
hydroxyethoxy)ethoxy]ethoxy}ethyl)-L-prolinamide (13 mg, 0.02 mmol, 1 equiv) and biotin-
OSu (7 mg, 0.02 mol, 1 equiv) were dissolved in DMF (0.2 mL) at rt. Triethylamine (4.0 μL, 
0.03 mmol, 1.5 equiv) was added. The reaction mixture was stirred at 25 °C for 12 h. The 
solvent was removed and the product was purified by HPLC (XTerra Prep RP C18, (19x150 
mm Waters)) (to afford 12 as a colorless oil (6 mg, 33 %). IR (film): 3265, 3075, 2920, 2865, 
1780, 1640, 1535, 1445, 1345, 1330, 1245, 1200, 1090, 1030, 940, 830, 645, 600, 545, 540, 
525, 510, 500 cm-1.1H NMR (400 MHz, MeOD): δ=4.49 (dd, 1H, 2J= 7.8, 3J= 5.1 Hz, H-6a), 
4.43 (dd, 1H, 2J= 8.6, 3J= 3.7 Hz, H-2, H-2’’) 4.33 (m, 2H, H-3a, H-2, H-2’’), 4.19 (d, 2H, 
4J= 2.4 Hz, H-13), 4.15 (dd, 1H, H-2’), 3.94 (dd, 1H, 2J= 17.0, 3J= 4.6 Hz, H-2’), 3.69-3.35 
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(m, 34H, (CH2-O)16, H2-5), 3.21 (m, 1H, CH), 2.93 (dd, 1H, 2J= 12.8, 3J= 5.0 Hz, H2-6) 2.86 
(t, 1H, 3J= 2.4 Hz, H-15), 2.71 (d, 1H, 2J= 12.7 Hz, H2-6), 2.40-1.45 (m, 16H, (CH2)8).13C 
NMR (100 MHz, MeOD): δ=176.0, 175.3, 174.0, 171.8, 169.9, 76.0, 73.7, 71.6, 71.55, 71.5, 
71.4, 71.3, 71.2, 70.3, 70.1, 70.1, 63.2, 62.2, 61.9, 61.7, 59.0, 57.0, 54.1, 47.8, 42.8, 41.0, 
40.6, 40.4, 36.4, 36.3, 32.9, 30.8, 29.6, 29.5, 29.4, 28.9, 26.7, 26.6, 25.7. HRMS (ESI): (m/z): 
calcd for C41H69N7O14S+H: 916.4702, found: 916.4717. [α]D25 = - 18 (c=0.05, CH2Cl2). 
[5-[3a, 4a, 6a)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-pentanoyl]-N-(3,6,9,12-
tetraoxa-pentadec-14-yn-1-yl)pentanamide (13) Biotin-OSu (0.83 g, 2.4 mmol, 1 equiv) 
followed by triethylamine (0.5 mL, 3.6 mmol, 1.5 equiv) were added to a solution of 3, 6, 9, 
12-tetraoxapentadec-14-yn-1-amine (0.56 g, 2.4 mmol, 1 equiv) in DMF (24 mL). The 
reaction mixture was stirred overnight at rt. The solvent was removed under reduced pressure 
and the desired product was purified by column chromatography (CH2Cl2/MeOH 95/5) to 
provide a colorless oil (560 mg, 51 %). IR (film): 3245, 2925, 2865, 1810, 1780, 1700, 1645, 
1550, 1460, 1350, 1325, 1305, 1265, 1245, 1210, 1090, 1035, 945, 860, 840, 760, 635, 600, 
540, 530, 505 cm-1.1H NMR (400 MHz, MeOD): δ=4.49 (dd, 1H, 2J= 8.0, 3J= 5.0 Hz, H-6a), 
4.31 (dd, 1H, 2J= 7.9, 3J= 4.5 Hz, H-3a), 4.19 (d, 2H, 4J= 2.5 Hz, H-13), 3.69-3.61 (m, 12H, 
(CH2-O)6, 3.56 (t, 2H, 3J= 5.3 Hz, CH2-O), 3.36 (m, 2H, CH2-O), 3.20 (m, 1H, H-4a), 2.93 
(dd, 1H 2J= 12.8, 3J= 5.0 Hz, H2-6), 2.85 (t, 1H, 3J= 2.4 Hz, H-15), 2.71 (d, 1H, 3J= 12.7 Hz, 
H2-6), 2.23 (t, 2H, 3J= 7.3 Hz, CH2), 1.77-1.41 (m, 6H, (CH2)3).13C NMR (100 MHz, MeOD): 
δ=176.22, 75.97, 71.55, 71.51, 71.50, 71.34, 71.23, 70.57, 70.11, 63.34, 61.60, 59.04, 56.98, 
41.04, 40.38, 36.77, 29.74, 29.48, 26.83, 26.28. HRMS (ESI): (m/z): calcd for 
C21H35N3O6S+H: 458.2325, found: 458.2337. [α]D25 = 22 (c=0.195, CH2Cl2). 
N-[14-(2,2-difluorocyclooct-3-yn-1-yl)-13-oxo-3,6,9-trioxa-12-azatetradec-1-yl]-5-(2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (16) The (2,2-difluorocyclooct-
3-yn-1-yl)acetic acid (10 mg, 0.05 mmol, 1 equiv) was dissolved with dry dichloromethane 
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(0.38 mL) in a flame-dried round-bottom flask and put under an argon atmosphere. A solution 
of amino-PEG-biotin (20.70 mg, 0.05 mmol, 1 equiv) and N-ethyldiisopropylamine (12.69 
mg, 0.07 mmol, 1.5 equiv) in dry DCM (0.38 mL) was added to the reaction mixture. The 
system was stirred at rt for 5 h, and then purified by flash chromatography (9:1 to 8:2 
EtOAc/MeOH) to afford a white solid (12.10 mg, 0.02 mmol, 41 %). IR (film) : 3265, 2930, 
2870, 2220, 1705, 1645, 1555, 1460, 1385, 1280, 1240, 1130, 1030, 1010, 940, 750, 690, 665, 
650, 605 cm-1.1H NMR (400 MHz, MeOD-d4) : δ= 4.50 (dd, 1H, 2J = 7.7, 3J= 5.0 Hz, H-34,), 
4.31(dd, 1H, 2J= 7.7, 3J= 4.5 Hz, H-30), 3.64 (app. d, 8H, 3J= 5.6 Hz H2-15, H2-16, H2-18, 
H2-19), 3.55 (t, 4H, 3J= 5.4 Hz, H2-34, H2-21), 3.37 (m, 4H, H2-12, H2-22), 3.21 (m, 1H, H-
29), 2.93 (dd, 1H, 2J= 12.8, 3J= 4.9 Hz, H2-35a), 2.83-2.74 (m, 1H, H-1), 2.71 (d, 1H, 2J= 
12.7 Hz, H2-35b), 2.51 (dd, 1H, 2J= 12.7, 3J= 3.8 Hz, H2-9a), 2.47-2.31 (m, 2H, H2-5), 2.22 
(app. t, 3H, 3J= 6.9 Hz, H2-25, H2-9b), 2.17-2.08 (m, 2H, H2-6), 1.86-1.51 (m, 6H, H2-26, H2-
28, H2-7), 1.48-1.29 (m, 4H, H2-27, H2-8) ppm.13C NMR (100 MHz, MeOD-d4) :δ=176.1, 
173.8, 166.1, 111.7, 111.5, 71.6, 71.27, 71.26, 70.6, 70.5, 63.3, 61.6, 57.0, 54.4, 41.0, 40.4, 
40.3, 36.7, 35.9, 33.77, 33.75, 33.3, 33.2, 29.8, 29.5, 28.9, 26.8, 20.6 ppm. HRMS (ESI): 
(m/z): calcd for C28H44F2N4O6S+H: 603.3028, found: 603.3027. [α]D25 = 130 (c=0.105, 
CH2Cl2). 
 
Cellular assays 
Cells and cell culture reagents 
Human fetal osteoblasts were derived by the explant technique from the femoral bone of a 12-
weeks old fetus according to a protocol accepted by the Lausanne Hospital and University 
Ethics Committee and with the mother’s oral and written approval (protocol No 51/01, 2008). 
The cells were used at passage 6 of the initial culture. Cells were routinely grown in DMEM 
medium containing 4.5 g/l glucose, 10% heat-inactivated fetal calf serum (FCS) and 
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penicillin/streptomycin (P/S). All cell culture reagents were obtained from Invitrogen, Basel, 
Switzerland. L-azidohomoalanine (AHA) was purchased from Invitrogen, bovine serum 
albumin (BSA), copper sulfate and tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) 
from Sigma-Aldrich, Buchs, Switzerland and the WST-1 reagent (2-(4-iodophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulphophenyl)-2H-teterazolium) from Roche Diagnostics, Rotkreuz, 
Switzerland. The click-reactions were performed in the BD FalconTM CultureSlides (BD 
Biosciences, Belgium). 
Experimental conditions for the click reactions: 
Human fetal osteoblasts (80-90 % confluent) were washed with warm (37°C) PBS and 
incubated in methionine-free DMEM culture medium containing 4.5 g/l glucose, antibiotics 
(P/S) and 3% FCS for 30-60 min to deplete methionine reserves.  Then they were incubated 
for 4 h in the presence of AHA (50 µM) in fresh complete culture medium. The culture 
medium was removed and the cell layer was washed twice with PBS. Then the click reactions 
were performed and efficacy of the reaction was evaluated by fluorescence microscopy or 
fresh complete medium was added and culture continued for assessing cell survival using the 
WST-1 test. 
Fluorescence microscopy experiments 
Click-reaction (Scheme 5A): Stock solutions of compounds 9, 10, 12, 13 (0.2 mM in PBS), 
TBTA (1.7 mM in 4:1 tbutanol:DMSO) and CuSO4 (20 mM in water) were prepared. For 
microscopy experiments, the click reaction was performed in a total volume of 500 µl, 
containing PBS (410 mL), compounds 9, 10, 12, 13 (20 µM), TBTA (80 µM) and CuSO4 (0.8 
mM) sequentially added to the cells. Incubation was performed for 1 h at 37 °C. The reaction 
mixture was removed and two washings with PBS allowed the complete removal of the 
different reagents. Streptavidin-Cy3 (Sigma-Aldrich) (1:100) and DAPI (4',6-diamidino-2-
phenylindole, Roche Diagnostics) (1 µg/mL in PBS) were then added and incubated with the 
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cells for 30 min in the dark. After two washings with PBS during 5 min in the dark, the cells 
were fixed using a 4 % p-formaldehyde solution at 4° C. Two additional washings with PBS 
were performed. The chamber was removed from the slide glass by using the chamber 
removal device and the evaluation of the click-reaction was performed by fluorescence 
microscopy and slides photographed under a fluorescence microscope (Zeiss Axioplan 2). 
Click-reaction (Scheme 5B): Stock solutions of compounds 12 and 13 (1 mM in PBS), 
CuSO4 (2 mM in water), THPTA (10 mM in PBS), aminoguanidine (50 mM in PBS) and 
sodium ascorbate (100 mM) were prepared. The reaction mixture containing compounds 12 or 
13 (100 µM), aminoguanidine (1 mM), CuSO4 (50 µM), THPTA (250 µM) and sodium 
ascorbate (2.5 mM) in PBS was pre-incubated for 1 h at 4 °C The cell culture medium was 
removed and the cell layer was washed twice with HBSS. For microscopy experiments, the 
reaction mixture was added to the cells at 4 °C for 5 min. The reaction mixture was removed 
and two washings with PBS at 37 °C allowed the complete removal of the different reagents. 
The cells were then fixed using a 4 % p-formaldehyde solution for 10 min at room 
temperature. After two washings with warm PBS, the cells were incubated with PBS 
containing 1 % BSA for 1 h at room temperature, then the labeling was performed as above. 
Click-reaction (Scheme 5C): Stock solution of compound 16 (2.5 mM in PBS:DMF (7:3)) 
was prepared. For microscopy experiments, the click reaction was performed in a solution 
containing compound 16 (100 µM) in DMEM containing additional HEPES (20 µM). 
Incubation was performed for 1 h at 25 °C. The reaction mixture was removed and two 
washings with PBS at 37 °C allowed the complete removal of the reagents. The cells were 
then fixed using a 4 % p-formaldehyde solution for 10 min at room temperature. After two 
washings with warm PBS, the cells were incubated with PBS containing 1 % BSA for 1 h at 
room temperature and the labeling was performed as above. 
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Evaluation of the conjugation of the ligands to the cells: The copper-free click reaction 
with compound 16 (100 µM) and the THPTA/copper-catalyzed click reaction with 
compounds  12 or 13 (100 µM) were performed on human fetal osteoblasts grown on 
histological slides and pre-incubated with AHA, and subsequently exposed to fluorescent 
streptavidin  to label biotin according to the described procedures. To evaluate for non-
specific binding, human fetal osteoblasts without pre-incubation with AHA were exposed to 
compounds 16 or 13 (100 µM) in the presence of the copper catalyst then to fluorescent 
streptavidin. The cell-associated fluorescence was determined by fluorescence microscopy 
(Zeiss Axioplan 2). For each treatment, a picture was taken under identical exposure 
conditions and the fluorescence of individual cells (20 cells per treatment) was quantified 
using Image J software. Results are the mean + sd of the mean fluorescence intensity (MFI) 
per cell. 
Alternatively, human fetal osteoblasts grown in 96-wells plates (Costar) and either copper-
free or THPTA/copper-catalyzed click reactions were performed with controls and the 
compound 16 (100 and 200 µM) or compounds 13 (100 and 200 µM) . The cells layers were 
carefully washed and 100 µl/well of a 1:1000 dilution of HRP (horse radish peroxidase)-
cojugated streptavidin (Dako, Baar, Switzerland, 0.83 mg/ml) in PBS containing 1% BSA 
were added for 30 min at 37°C, then after washing with PBS containing 0.05% Tween, 100 
µl/well of a 3,3,5,5’-tetramethylbenzidine (TMB)-H2O2 solution were added and the increase 
of absorbance at 450 nm was recorded for 30 min at 37 °C in a thermostated absorbance 
multiwall-plate reader (iEMS, LabSystems). Then the liquid was aspirated and the cell layers 
were lyzed in 20 µl/well of lysis buffer (20 mM Tris-HCl, 137 mM NaCl, 10% v/v glycerol, 
1% v/v NP40, 1% w/v CHAPS) then µl/well of PBS-0.1% Triton X-100 were added, and the 
protein content of the lyzed cells was quantified using the BCA kit (BCA Protein Assay Kit, 
16 
 
Pierce, Rockford, USA) and bovine serum albumin as standard, according to the provider’s 
protocol. 
 
WST-1 Cell Viability Assay  
Cytotoxicity of the click reagents: cell cultures were treated in culture medium with various 
concentrations of the reagents for 1 h at 37 °C. The culture medium was removed and the cells 
were washed twice with HBSS, then cultures were continued in complete medium for 24 h to 
96 h. The culture medium was removed, cells were rinsed with culture medium without 
phenol red (Invitrogen) and incubated with the WST-1 reagent (Roche Diagnostics), diluted 
1:10 in culture medium without phenol red and without FCS for 3 h. Optical density of the 
supernatants was measured at 450 nm in a multiwell-plate reader (iEMS Reader MF, 
Labsystems, Bioconcept) against a blank containing culture medium and WST-1. 
Copper-catalyzed click reaction: cell cultures were treated with the reaction mixture 
containing compound 13 (20 µM), CuSO4 (0.8 mM), TBTA (80 µM) in PBS at 37 °C for 1 h. 
The culture medium was removed and the cells were washed twice with HBSS, then cultures 
were continued in complete medium. Cell survival was evaluated after 24 h to 96 h as above.  
Modified copper-catalyzed click reaction: cell cultures were treated with the reaction 
mixture containing compound 13 (100 µM), aminoguanidine (1 mM), CuSO4 (50 µM), 
THPTA (250 µM) and sodium ascorbate (2.5 mM) in PBS at 4 °C for 5 min. Then cell 
survival was evaluated after 24 h to 96 h as above. 
Copper-free click reaction: cell cultures were treated with compound 16 (100 µM) in 
DMEM containing 4.5 g/l glucose, antibiotics (P/S) and additional HEPES (20 µM) for 1 h at 
room temperature. Then cell survival was evaluated after 24 h to 96 h as above. 
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Results  
Synthesis of chemical ligands for functionalization of cell proteins  
Following the procedure of Svensson,22 tetraethylene glycol was transformed into mono-azide 
2 in 61% yield (Scheme 1). The alkynyl functionality was introduced by alkylation in the 
presence of propargyl bromide, followed by Staudinger reduction23,24 to provide the amine 3 
in good yield. Coupling with semi-protected L-glutamic acid 4 and subsequent acidic 
cleavage of the resulting tert-butyl ester afforded the intermediate derivative 6, presenting 
three orthogonal groups for the successive introduction of amino acids or peptides, a labeling 
agent and a group for the attachment to cell surface glycoproteins. Further coupling with 
protected amino acids was performed in the presence of PyBOP, at -5°C, to deliver the 
intermediates 7 and 8 in good yields (Scheme 2). 
Cleavage of the carbamate under basic conditions, followed by conjugation with an activated 
biotin moiety afforded compounds 9 and 10, ready to undergo copper catalyzed [3+2] 
cycloaddition to azido-modified cell surface glycoproteins. A similar route was applied to 
introduce a Gly-Pro dipeptide. Boc-Gly-Pro was functionalized in 95% yield with an amino-
tetraethylene glycol chain to increase hydrophilicity. Further coupling with intermediate 6 at 
low temperature and derivatization with a biotin label afforded compound 12 as an alkynyl 
substrate for click-reaction with azido-modified cellular proteins.  
The simpler model molecule 13 was also prepared to determine the appropriate conditions for 
the copper-mediated click reaction. The synthesis was performed starting from amine 3 which 
was coupled with an activated biotin in the presence of triethylamine (Scheme 3). The desired 
product 13 was provided in 51 % yield. 
To avoid the use of a metal catalyst, a chemical ligand suitable for copper-free click reaction 
was also synthesized. The difluorinated cyclooctyne (DIFO) moiety developed by Bertozzi 
and co-workers11 which has demonstrated a high potential to bind to cell surface proteins via a 
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copper-free click reaction was introduced in one of our conjugates for the functionalization of 
human fetal osteoblasts. The DIFO 14 was coupled with the tetraethylene glycol-biotin 
derivative 15 in the presence of PyBOP at room temperature to provide the model compound 
16 (Scheme 4) which can react with azido-modifed cell proteins.  
 
Biological evaluation of the synthesized compounds using click reactions 
The cell experiments were designed to determine which experimental coupling conditions 
represent the best compromise between chemical reactivity and biocompatibility. The 
functionalization of the cell proteins of human primary fetal osteoblasts was performed under 
three different experimental conditions: two copper-catalyzed click reactions in the presence 
of different copper complexes and protective reagents and one copper-free click reaction 
performed in cell culture medium without fetal calf serum (FCS) (Scheme 5). The 
biocompatibility of the copper catalyst and of the synthesized compounds was determined 
using assessment of cell viability with the WST-1 assay up to 96 h after the click reactions.  
In order to express azide-modified proteins, human fetal osteoblasts were cultured in the 
presence of the non-natural amino acid L-azidohomoalanine (AHA) which can replace 
methionine without cell alterations,6 thus, allowing the insertion of an azide moiety in cellular 
proteins. Proliferating primary human fetal osteoblasts were labeled for 4 h with AHA added 
to methionine-free cell culture medium before performing the click reactions. The model 
molecule 13 was used first to establish the optimal conditions for the copper-mediated click 
reaction with cells. Different ratios of copper sulfate to the copper-reducing agent tris[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) were evaluated at a fixed concentration 
(10 µM) of 13. Reported standard conditions use 1 mM copper sulfate and 0.1 mM TBTA at 
25°C.6 Here, the reaction was performed at 37°C in phosphate buffered saline pH 7.4 (PBS) 
for 1 h in order to decrease the loading of copper catalyst. Cell nuclei labeling was performed 
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with the fluorescent reporter 4',6-diamidino-2-phenylindole  (DAPI). Detection of cell surface 
ligation of 13, as evidenced by the binding of fluorescent streptavidin-Cy3 to the reporter 
biotin moiety of the prepared conjugate, was demonstrated by fluorescence microscopy 
(Figure 1). The results showed that a ratio of copper to TBTA of 10 to 1 was optimal, 
confirming published information.25 Therefore, for further experiments the concentrations 
used were 0.8 mM copper sulfate and 0.08 mM TBTA. Then we determined the optimal 
concentration of the alkyne moiety for performing the click reaction with cells using 
increasing concentrations of 13. The best results were obtained with a 20 µM concentration of 
13 (Figure 1B), whereas in the absence of preincubation of cells with AHA no labeling was 
detected (Figure 1A). Thus, these conditions were applied for the functionalization of the fetal 
osteoblast with compounds 9, 10 and 12. (Figure 1C-1E). The functionalization of cells, as 
evidenced by the binding of fluorescent streptavidin to cells, was observed for all compounds 
9, 10, 12 and 13.  
However, an important and very rapid cytotoxicity was observed under these experimental 
conditions (Figure 2A). While ligands 9, 10, 12 and 13 did not show any cytotoxicity at 
concentrations up to 100 µM (Figure 2C), the catalytic system TBTA/CuSO4 induced cell 
death after 1 h exposure at concentrations higher than 0.8 mM in copper (Figure 2B). This 
significant cytotoxicity of the copper catalytic promoter prompted us to explore alternative 
conditions for the functionalization of the fetal osteoblasts by click reaction. 
Hong and co-workers have recently reported26 a modified copper-catalyzed click reaction 
with decreased cytotoxicity that allows the labeling of living cells. In this modification, the 
use of the water soluble tris-(hydroxypropyltriazolylmethyl)amine (THPTA) promoter in the 
catalytic system in the presence of sodium ascorbate increases the reaction rate allowing a 
lower copper concentration and captures the reactive oxygen species (ROS) generated by the 
metal, thus decreasing cytotoxicity. Aminoguanidine also added to the reaction mixture traps 
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dehydroascorbate and its decomposition products before they can react with protein side 
chains.26 These reaction conditions were applied for the functionalization of fetal osteoblasts 
with 12 and 13. Aminoguanidine (1 mM), 12 or 13 (100 µM), copper sulfate (50 µM), 
THPTA (250 µM) and sodium ascorbate (2.5 mM) were sequentially added to the cells. After 
5 min at 4°C, the reagents were removed and labeling of cell nuclei with DAPI and detection 
of streptavidin-Cy3 binding by fluorescence microscopy were performed. The 
functionalization of the cell surface was observed for both 12 and 13 (Figure 3B and 3C), 
whereas in the absence of preincubation of cells with AHA no labeling was detected (Figure 
3A). After the reaction, the cells were washed free of the reagents and cultured in complete 
culture medium and the WST-1 assay was performed after 24, 48, 72 and 96 h (Figure 4A). 
The results demonstrated a good cell survival since human fetal osteoblasts survived and 
proliferated for up to four days after the copper-catalyzed click reaction performed with the 
THPTA ligand in the presence of aminoguanidine.  
Finally, the functionalization of the human fetal osteoblasts by copper-free click reaction with 
compound 16 was evaluated. Compounds presenting activated difluorinated cyclooctyne11 can 
react with azide moieties without copper catalyst since the loss of the ring strain (18 kcal/mol) 
and the decrease of the lowest unoccupied molecular orbital (LUMO) energy by the two 
fluoride atoms allow the decrease of the activation energy of the click reaction. The copper-
free click reaction of compound 16 (100 µM) with human fetal osteoblasts was performed at 
room temperature for 1 h in culture medium without FCS containing additional HEPES (20 
µM) for buffering. Cell nuclei were labeled with DAPI and the cell functionalization was 
demonstrated by fluorescence microscopy using Cy3-streptavidin (Figure 3E), whereas in the 
absence of preincubation of cells with AHA no labeling was detected (Figure 3D). An 
excellent cell survival rate for up to 96 h after the cycloaddition process was evidenced 
(Figure 4B). 
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The level of conjugation of compounds 12, 13, 16 or in the absence of AHA (for non-specific 
binding) to human fetal osteoblasts was evaluated following click reactions performed under 
non-cytotoxic conditions using two techniques. The cell-associated fluorescence of individual 
cells (20 cells per treatment) was quantified under identical exposure conditions using Image J 
software as the mean fluorescence intensity (MFI) per cell (Figure 5A), showing a slightly 
increased conjugation rate of compounds 16 under copper-free click-reaction and 12 under 
copper-catalyzed click-reaction compared to compound 13 under copper-catalyzed click-
reaction. Quantification was also performed using HRP-streptavidin and a cellular-ELISA 
assay. The increase in cell-bound HRP enzymatic activity per well was related to the amount 
of cell proteins per well (Figure 5B), showing a dose-dependent binding of both compounds 
13 and 16, without noticeable differences between both, suggesting that copper-free and 
protected copper-mediated click reactions performed with comparable efficacy.       
 
Discussion  
Human fetal cells represent an appealing approach for the seeding of implant biomaterials for 
tissue engineering, including bone engineering, as these cells do not require the use of anti-
graft rejection treatment.16 This study has demonstrated the possibility to functionalize 
primary human fetal osteoblasts through click chemistry with amino acid-containing chemical 
ligands able to maintain cell survival and proliferation. While ligands 9, 10 and 12 were easily 
conjugated to azido-modified surface proteins of fetal osteoblasts in the presence of a Cu(I) 
promoter, these reaction conditions induced a drastic loss of cell viability even with reduced 
reaction time. This major drawback was circumvented by the introduction of a highly reactive 
alkynyl functionality in the ligands (compound 16), thus avoiding the use of a copper catalyst 
in the cycloaddition process. Nevertheless, as the preparation of DIFO containing ligands11 is 
more complex, requiring a much higher number of steps compared to a simple alkynyl 
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containing ligand, we turned our attention to the protection of cells from the Cu(I) catalyst by 
the aminoguanidine-THPTA combination recently proposed by Hong et al.26 In our hands, 
these experimental conditions applied to primary human fetal osteoblasts resulted in both 
efficient cell functionalization and excellent cell survival. In addition, all chemical ligands 
prepared to promote further cell adhesion and proliferation showed perfect biocompatibility 
with the studied cells. 
In conclusion, we have shown that biocompatible biotin-containing ligands can be designed 
and synthesized for conjugation to cellular azido-modified proteins of primary human fetal 
osteoblasts. Using the click reaction, cell functionalization was probed with fluorescent 
streptavidin. Three methods of cell functionalization were explored allowing a comparison in 
term of efficiency and biocompatibility of different experimental conditions. The use of the 
classical TBTA/CuSO4 catalytic system led to efficient conjugation but suffered from high 
cytotoxicity which prevented further application for developing implant biomaterials. 
Protection of the cells from the copper catalyst through the use of the THPTA-ascorbate 
system in the presence of aminoguanidine led to a good reaction rate while maintaining a high 
level of cell viability. Similarly, good reaction rates and excellent cell viability were observed 
for the copper-free click reaction. Incorporation of peptidic components in the ligands was 
possible maintaining the efficacy and biocompatibility of functionalization and the survival of 
the primary human fetal osteoblasts. These results open the route for the use of peptide-
functionalized human fetal osteoblasts as seeding components for implant biomaterials. 
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aAbbreviations List 
AHA   L-azidohomoalanine 
BSA  bovine serum albumin 
DAPI  4',6-diamidino-2-phenylindole   
DIFO   difluorinated cyclooctyne 
DIPEA N,N-diisopropylethylamine  
DMEM Dulbecco modified Eagle medium 
FCS  fetal calf serum 
HBSS  Hank’s buffered salt solution 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP  horse radish peroxidase 
LUMO lowest unoccupied molecular orbital 
PBS  phosphate buffered saline 
P/S  penicillin/streptomycin 
PyBOP benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
ROS  reactive oxygen species 
TBTA   tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
TMB  3,3,5,5’-tetramethylbenzidine 
THPTA tris-(hydroxypropyltriazolylmethyl)amine 
WST-1 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-teterazolium 
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Scheme 
Scheme 1: Synthesis of the glutamic acid derivative containing three orthogonal groups. 
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Scheme 2: Synthesis of ligands for cell functionalization 
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Scheme 3: Synthesis of the model molecule for the copper click reaction 
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Scheme 4: Synthesis of the model molecule for the copper-free click reaction 
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Scheme 5. Experimental conditions for the functionalization of human primary fetal 
osteoblasts. 
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Figures and Figure Legends 
 
  
   
   
 
Figure 1: TBTA/copper-catalyzed click reaction performed on human fetal osteoblasts. 
A. To evaluate for non-specific binding, human fetal osteoblasts without pre-incubation with 
AHA were exposed to the TBTA/copper catalyst and biotin-containing compound 13, then to 
fluorescent streptavidin to label biotin and DAPI to label nuclei. B-E. Human fetal osteoblasts  
were pre-incubated with AHA and subsequently exposed for 1 h at 37 °C to compounds 13 
(B), 9 (C), 10 (D) or 12 (E) using TBTA/copper-catalyzed click reaction, then to fluorescent 
streptavidin to label biotin and DAPI to label cell nuclei. Bound compounds fluoresce red and 
cell nuclei blue. 
C D E 
A A B 
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Figure 2: Evaluation of the biocompatiblity of the TBTA/copper catalyst and of compounds 9, 
10, 12 and 13. 
A. TBTA/copper-catalyzed click reaction was performed for 1 h at 37 °C between compound 
13 and human fetal osteoblasts pre-incubated with AHA, cell culture medium was changed 
and culture was continued for 24 to 48 h. Then the WST-1 assay was performed. B. Human 
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fetal osteoblasts without pre-incubation with AHA were exposed for 1 h at 37 °C to the 
TBTA/copper catalytic system at increasing concentrations of the catalysts, then the WST-1 
assay was performed. C.  Human fetal osteoblasts without pre-incubation with AHA were 
exposed for 1 h at 37 °C to compound 9, 10, 12 and 13 in the absence of TBTA/copper 
catalysts, cell culture medium was changed and culture was continued for 24 h, then the 
WST-1 was performed. Results are the means + sd of triplicate wells of a representative 
experiment out of 3 independent experiments.  
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Figure 3: Modified THPTA/copper-catalyzed and copper-free click reactions performed on 
human fetal osteoblasts. 
A. To evaluate for non-specific binding, human fetal osteoblasts without pre-incubation with 
AHA were exposed to biotin-containing compound 13 in the presence of the modified 
THPTA/copper catalyst, then to fluorescent streptavidin to label biotin and DAPI to label cell 
nuclei. B. and C. Human fetal osteoblasts were pre-incubated with AHA and subsequently 
exposed for 5 min at 4 °C to compounds 13 (B) or 12 (C) using the THPTA/copper-catalyzed 
click reaction, then exposed to fluorescent streptavidin to label biotin and to DAPI to label 
cell nuclei. D. To evaluate for non-specific binding, human fetal osteoblasts without pre-
incubation with AHA were exposed to biotin-containing compound 16, then to fluorescent 
streptavidin to label biotin and DAPI to label cell nuclei. E. Human fetal osteoblasts were pre-
incubated with AHA and subsequently exposed to compound 16 for 1 h at 25 °C using 
copper-free click reaction, then to fluorescent streptavidin to label biotin and to DAPI to label 
cell nuclei. Bound compounds fluoresce red and cell nuclei blue. 
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Figure 4: Evaluation of human fetal osteoblasts viability after modified THPTA/copper-
catalyzed and copper-free click reactions. 
A. Modified THPTA/copper-click reaction was performed for 5 min at 4 °C between 
compound 13 and human fetal osteoblasts pre-incubated with AHA, cell culture medium was 
changed and culture was continued for 24 to 96 h, then the WST-1 assay was performed. B. 
Copper-free click reaction was performed for 1 h at 25 °C between compound 16 and human 
fetal osteoblasts pre-incubated with AHA, cell culture medium was changed and culture was 
continued for 24 to 96 h, then the WST-1 assay was performed.  Results are the means + sd of 
triplicate wells of a representative experiment out of 3 independent experiments. 
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Figure 5: Evaluation of compounds conjugation to the cells 
Following click reactions performed on human fetal osteoblasts under non-cytotoxic 
conditions with compound 12 or 13, or 16 or in the absence of AHA or the compounds (for 
non-specific binding)  (A): the cell-associated fluorescence was quantified using 100 μM of 
either compounds 12, 13 or 16. Results are expressed as the mean fluorescence intensity 
(MFI) per cell + sd; or (B) the enzymatic activity of cell-associated HRP-strptavidin was 
related to the protein content of the cells. Control: nocompound or AHA added to the cells, 16 
or 13: cells exposed to the compounds in the absence of AHA; AHA: cells exposed to AHA in 
the absence of the compound; AHA+16/+13: cells exposed to AHA and the compounds. 
Results are expressed as the ratio of the cell-bound HRP activity to the protein cotent per well. 
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